Stockreport

U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy

Pfizer, Inc.  (PFE) 
Last pfizer, inc. earnings: 4/28 06:45 am Check Earnings Report
PDF BRAFTOVI plus cetuximab is the first-and-only FDA-approved targeted regimen specifically for adults with previously treated metastatic CRC with a BRAFV600E mutation N [Read more]